<DOC>
	<DOCNO>NCT00524186</DOCNO>
	<brief_summary>RATIONALE : Sunitinib may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Drugs use chemotherapy , irinotecan , fluorouracil , leucovorin , work different way stop growth tumor cell , either kill cell stop divide . Giving sunitinib together combination chemotherapy may kill tumor cell . PURPOSE : This phase I trial study side effect best dose sunitinib give together irinotecan , fluorouracil , leucovorin treat patient advanced stomach cancer gastroesophageal cancer .</brief_summary>
	<brief_title>Sunitinib , Irinotecan , Fluorouracil , Leucovorin In Treating Patients With Advanced Stomach Cancer Gastroesophageal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose sunitinib malate administer FOLFIRI chemotherapy comprise irinotecan hydrochloride , fluorouracil , leucovorin calcium patient advanced gastroesophageal cancer . Secondary - Determine response rate , overall survival , progression-free survival patient treat regimen . - Determine change circulate endothelial precursor cell number VEGF expression result therapy change correlate improve response survival . - Document pharmacokinetic interaction irinotecan hydrochloride sunitinib malate . - Study pharmacokinetics sunitinib malate day 14 ( steady state ) day 42 ( 6 week continuous dose ) . OUTLINE : Patients receive oral sunitinib malate day -7 daily day 2-28 course 1 day 1-28 subsequent course . Patients also receive FOLFIRI chemotherapy comprise irinotecan hydrochloride IV 90 minute , fluorouracil IV continuously 46 hour , leucovorin calcium IV 2 hour begin day 1 15 . Treatment repeat every 4 week 12 month absence disease progression unacceptable toxicity . Blood collect baseline periodically study pharmacokinetic biomarker correlative study . Samples analyze flow cytometry ass circulate endothelial cell VEGF expression . After completion study treatment , patient follow 4 week .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Inclusion criterion : Histologically confirm diagnosis 1 following : Locally advance unresectable gastric cancer Metastatic gastric adenocarcinoma Metastatic gastroesophageal junction ( GEJ ) adenocarcinoma Esophageal adenocarcinomas involvement GEJ allow Exclusion criterion : Symptomatic , uncontrolled CNS metastasis PATIENT CHARACTERISTICS : Inclusion criterion : ECOG performance status 01 Life expectancy &gt; 12 week WBC ≥ 3,000/μL Platelet count ≥ 100,000/μL Creatinine ≤ 1.5 mg/dL Bilirubin ≤ 1.5 mg/dL Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Exclusion criterion : Uncontrolled infection Uncontrolled serious medical disease Uncontrolled hypertension Coagulopathy bleed disorder History allergic reaction attribute compound similar chemical biological composition sunitinib malate agent use study PRIOR CONCURRENT THERAPY : Inclusion criterion : No prior chemotherapy metastatic disease Concurrent therapeutic anticoagulation allow Exclusion criterion : Other concurrent investigational therapy Concurrent combination antiretroviral therapy HIVpositive patient Major surgery radiotherapy within past 3 week</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>stage III gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>adenocarcinoma esophagus</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>adenocarcinoma stomach</keyword>
</DOC>